866-997-4948(US-Canada Toll Free)

United States Pulmonary Arterial Hypertension (PAH) Market Report 2018

Published By :

QYResearch

Published Date : Jun 2018

Category :

Pharmaceutical

No. of Pages : 100 Pages

In this report, the United States Pulmonary Arterial Hypertension (PAH) market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Pulmonary Arterial Hypertension (PAH) in these regions, from 2013 to 2025 (forecast).

United States Pulmonary Arterial Hypertension (PAH) market competition by top manufacturers/players, with Pulmonary Arterial Hypertension (PAH) sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena
...

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Hospital
Clinic

Table of Contents

United States Pulmonary Arterial Hypertension (PAH) Market Report 2018
1 Pulmonary Arterial Hypertension (PAH) Overview
1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH)
1.2 Classification of Pulmonary Arterial Hypertension (PAH) by Product Category
1.2.1 United States Pulmonary Arterial Hypertension (PAH) Market Size (Sales Volume) Comparison by Type (2013-2025)
1.2.2 United States Pulmonary Arterial Hypertension (PAH) Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
1.2.3 Prostacyclin and Prostacyclin Analogs
1.2.4 SGC Stimulators
1.2.5 ERA
1.2.6 PDE-5
1.3 United States Pulmonary Arterial Hypertension (PAH) Market by Application/End Users
1.3.1 United States Pulmonary Arterial Hypertension (PAH) Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
1.3.2 Hospital
1.3.3 Clinic
1.4 United States Pulmonary Arterial Hypertension (PAH) Market by Region
1.4.1 United States Pulmonary Arterial Hypertension (PAH) Market Size (Value) Comparison by Region (2013-2025)
1.4.2 The West Pulmonary Arterial Hypertension (PAH) Status and Prospect (2013-2025)
1.4.3 Southwest Pulmonary Arterial Hypertension (PAH) Status and Prospect (2013-2025)
1.4.4 The Middle Atlantic Pulmonary Arterial Hypertension (PAH) Status and Prospect (2013-2025)
1.4.5 New England Pulmonary Arterial Hypertension (PAH) Status and Prospect (2013-2025)
1.4.6 The South Pulmonary Arterial Hypertension (PAH) Status and Prospect (2013-2025)
1.4.7 The Midwest Pulmonary Arterial Hypertension (PAH) Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Pulmonary Arterial Hypertension (PAH) (2013-2025)
1.5.1 United States Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2025)
1.5.2 United States Pulmonary Arterial Hypertension (PAH) Revenue and Growth Rate (2013-2025)

2 United States Pulmonary Arterial Hypertension (PAH) Market Competition by Players/Suppliers
2.1 United States Pulmonary Arterial Hypertension (PAH) Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Pulmonary Arterial Hypertension (PAH) Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Pulmonary Arterial Hypertension (PAH) Average Price by Players/Suppliers (2013-2018)
2.4 United States Pulmonary Arterial Hypertension (PAH) Market Competitive Situation and Trends
2.4.1 United States Pulmonary Arterial Hypertension (PAH) Market Concentration Rate
2.4.2 United States Pulmonary Arterial Hypertension (PAH) Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Pulmonary Arterial Hypertension (PAH) Manufacturing Base Distribution, Sales Area, Product Type

3 United States Pulmonary Arterial Hypertension (PAH) Sales (Volume) and Revenue (Value) by Region (2013-2018)
3.1 United States Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Region (2013-2018)
3.2 United States Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Region (2013-2018)
3.3 United States Pulmonary Arterial Hypertension (PAH) Price by Region (2013-2018)

4 United States Pulmonary Arterial Hypertension (PAH) Sales (Volume) and Revenue (Value) by Type (Product Category) (2013-2018)
4.1 United States Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Type (2013-2018)
4.3 United States Pulmonary Arterial Hypertension (PAH) Price by Type (2013-2018)
4.4 United States Pulmonary Arterial Hypertension (PAH) Sales Growth Rate by Type (2013-2018)

5 United States Pulmonary Arterial Hypertension (PAH) Sales (Volume) by Application (2013-2018)
5.1 United States Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Application (2013-2018)
5.2 United States Pulmonary Arterial Hypertension (PAH) Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 United States Pulmonary Arterial Hypertension (PAH) Players/Suppliers Profiles and Sales Data
6.1 Actelion
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Pulmonary Arterial Hypertension (PAH) Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Sales, Revenue, Price and Gross Margin (2013-2018)
6.1.4 Main Business/Business Overview
6.2 Gilead Sciences
6.2.2 Pulmonary Arterial Hypertension (PAH) Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Sales, Revenue, Price and Gross Margin (2013-2018)
6.2.4 Main Business/Business Overview
6.3 United Therapeutics
6.3.2 Pulmonary Arterial Hypertension (PAH) Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Sales, Revenue, Price and Gross Margin (2013-2018)
6.3.4 Main Business/Business Overview
6.4 GlaxoSmithKline
6.4.2 Pulmonary Arterial Hypertension (PAH) Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Sales, Revenue, Price and Gross Margin (2013-2018)
6.4.4 Main Business/Business Overview
6.5 Pfizer
6.5.2 Pulmonary Arterial Hypertension (PAH) Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Sales, Revenue, Price and Gross Margin (2013-2018)
6.5.4 Main Business/Business Overview
6.6 Bayer
6.6.2 Pulmonary Arterial Hypertension (PAH) Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Sales, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Main Business/Business Overview
6.7 Arena
6.7.2 Pulmonary Arterial Hypertension (PAH) Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Arena Pulmonary Arterial Hypertension (PAH) Sales, Revenue, Price and Gross Margin (2013-2018)
6.7.4 Main Business/Business Overview
...

7 Pulmonary Arterial Hypertension (PAH) Manufacturing Cost Analysis
7.1 Pulmonary Arterial Hypertension (PAH) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH)

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Pulmonary Arterial Hypertension (PAH) Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Major Manufacturers in 2017
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Pulmonary Arterial Hypertension (PAH) Market Size (Value and Volume) Forecast (2018-2025)
11.1 United States Pulmonary Arterial Hypertension (PAH) Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Pulmonary Arterial Hypertension (PAH) Sales Volume Forecast by Type (2018-2025)
11.3 United States Pulmonary Arterial Hypertension (PAH) Sales Volume Forecast by Application (2018-2025)
11.4 United States Pulmonary Arterial Hypertension (PAH) Sales Volume Forecast by Region (2018-2025)

12 Research Findings and Conclusion

13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer

List of Table

List of Tables and Figures

Figure Product Picture of Pulmonary Arterial Hypertension (PAH)
Figure United States Pulmonary Arterial Hypertension (PAH) Market Size (K Units) by Type (2013-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Volume Market Share by Type (Product Category) in 2017
Figure Prostacyclin and Prostacyclin Analogs Product Picture
Figure SGC Stimulators Product Picture
Figure ERA Product Picture
Figure PDE-5 Product Picture
Figure United States Pulmonary Arterial Hypertension (PAH) Market Size (K Units) by Application (2013-2025)
Figure United States Sales Market Share of Pulmonary Arterial Hypertension (PAH) by Application in 2017
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure United States Pulmonary Arterial Hypertension (PAH) Market Size (Million USD) by Region (2013-2025)
Figure The West Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales (K Units) and Growth Rate (2013-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Market Major Players Product Sales Volume (K Units) (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Sales (K Units) of Key Players/Suppliers (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Pulmonary Arterial Hypertension (PAH) Sales Share by Players/Suppliers
Figure 2017 United States Pulmonary Arterial Hypertension (PAH) Sales Share by Players/Suppliers
Figure United States Pulmonary Arterial Hypertension (PAH) Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Pulmonary Arterial Hypertension (PAH) Revenue Share by Players/Suppliers
Figure 2017 United States Pulmonary Arterial Hypertension (PAH) Revenue Share by Players/Suppliers
Table United States Market Pulmonary Arterial Hypertension (PAH) Average Price (USD/Unit) of Key Players/Suppliers (2013-2018)
Figure United States Market Pulmonary Arterial Hypertension (PAH) Average Price (USD/Unit) of Key Players/Suppliers in 2017
Figure United States Pulmonary Arterial Hypertension (PAH) Market Share of Top 3 Players/Suppliers
Figure United States Pulmonary Arterial Hypertension (PAH) Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Pulmonary Arterial Hypertension (PAH) Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Pulmonary Arterial Hypertension (PAH) Product Category
Table United States Pulmonary Arterial Hypertension (PAH) Sales (K Units) by Region (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Sales Share by Region (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Share by Region (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Market Share by Region in 2017
Table United States Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Revenue Share by Region (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Region (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Region in 2017
Table United States Pulmonary Arterial Hypertension (PAH) Price (USD/Unit) by Region (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Sales (K Units) by Type (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Sales Share by Type (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Share by Type (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Market Share by Type in 2017
Table United States Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) by Type (2013-2018)
Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) by Type in 2017
Table United States Pulmonary Arterial Hypertension (PAH) Price (USD/Unit) by Types (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Growth Rate by Type (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Sales (K Units) by Application (2013-2018)
Table United States Pulmonary Arterial Hypertension (PAH) Sales Market Share by Application (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Market Share by Application (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Market Share by Application in 2017
Table United States Pulmonary Arterial Hypertension (PAH) Sales Growth Rate by Application (2013-2018)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Growth Rate by Application (2013-2018)
Table Actelion Basic Information List
Table Actelion Pulmonary Arterial Hypertension (PAH) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Actelion Pulmonary Arterial Hypertension (PAH) Sales Growth Rate (2013-2018)
Figure Actelion Pulmonary Arterial Hypertension (PAH) Sales Market Share in United States (2013-2018)
Figure Actelion Pulmonary Arterial Hypertension (PAH) Revenue Market Share in United States (2013-2018)
Table Gilead Sciences Basic Information List
Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Gilead Sciences Pulmonary Arterial Hypertension (PAH) Sales Growth Rate (2013-2018)
Figure Gilead Sciences Pulmonary Arterial Hypertension (PAH) Sales Market Share in United States (2013-2018)
Figure Gilead Sciences Pulmonary Arterial Hypertension (PAH) Revenue Market Share in United States (2013-2018)
Table United Therapeutics Basic Information List
Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Sales Growth Rate (2013-2018)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Sales Market Share in United States (2013-2018)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Revenue Market Share in United States (2013-2018)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Sales Growth Rate (2013-2018)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Sales Market Share in United States (2013-2018)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Revenue Market Share in United States (2013-2018)
Table Pfizer Basic Information List
Table Pfizer Pulmonary Arterial Hypertension (PAH) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Pfizer Pulmonary Arterial Hypertension (PAH) Sales Growth Rate (2013-2018)
Figure Pfizer Pulmonary Arterial Hypertension (PAH) Sales Market Share in United States (2013-2018)
Figure Pfizer Pulmonary Arterial Hypertension (PAH) Revenue Market Share in United States (2013-2018)
Table Bayer Basic Information List
Table Bayer Pulmonary Arterial Hypertension (PAH) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Bayer Pulmonary Arterial Hypertension (PAH) Sales Growth Rate (2013-2018)
Figure Bayer Pulmonary Arterial Hypertension (PAH) Sales Market Share in United States (2013-2018)
Figure Bayer Pulmonary Arterial Hypertension (PAH) Revenue Market Share in United States (2013-2018)
Table Arena Basic Information List
Table Arena Pulmonary Arterial Hypertension (PAH) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Arena Pulmonary Arterial Hypertension (PAH) Sales Growth Rate (2013-2018)
Figure Arena Pulmonary Arterial Hypertension (PAH) Sales Market Share in United States (2013-2018)
Figure Arena Pulmonary Arterial Hypertension (PAH) Revenue Market Share in United States (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH)
Figure Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH)
Figure Pulmonary Arterial Hypertension (PAH) Industrial Chain Analysis
Table Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Major Players/Suppliers in 2017
Table Major Buyers of Pulmonary Arterial Hypertension (PAH)
Table Distributors/Traders List
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Volume (K Units) and Growth Rate Forecast (2018-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Price (USD/Unit) Trend Forecast (2018-2025)
Table United States Pulmonary Arterial Hypertension (PAH) Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Volume (K Units) Forecast by Type in 2025
Table United States Pulmonary Arterial Hypertension (PAH) Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Volume (K Units) Forecast by Application in 2025
Table United States Pulmonary Arterial Hypertension (PAH) Sales Volume (K Units) Forecast by Region (2018-2025)
Table United States Pulmonary Arterial Hypertension (PAH) Sales Volume Share Forecast by Region (2018-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Volume Share Forecast by Region (2018-2025)
Figure United States Pulmonary Arterial Hypertension (PAH) Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *